Diadenosine polyphosphates regulate cytosolic calcium in human fibroblast cells by interaction with P2x purinoceptors coupled to phospholipase C

Biochim Biophys Acta. 1996 Jun 13;1312(2):145-50. doi: 10.1016/0167-4889(96)00035-3.

Abstract

The effects of diadenosine pentaphosphate (AP5A), and diadenosine hexaphosphate (AP6A) on the cytosolic-free Ca2+ concentration ([Ca2+]i) were evaluated in cultured human fibroblast cells (HF cells) using the fluorescent dye technique. AP5A, and AP6A concentration-dependently increased [Ca2+]i in HF cells. The addition of 10 mumol/1 AP5A and AP6A significantly increased [Ca2+]i in HF cells from 71 +/- 3 nmol/1 (n = 184) to 241 +/- 39 nmol/1 (n = 11; P < 0.001 compared to resting value) and to 227 +/- 26 nmol/1 (n = 23; P < 0.001), respectively. The purinoceptor P2 blockers, suramin and pyridoxal-phosphate-6-azophenyl-2',4'-disulphonic acid (PPADS), inhibited the diadenosine polyphophate-induced [Ca2+]i increase, whereas the P2y purinoceptor blocker, reactive blue, had no effect. Adenosinetriphosphate (ATP) and the P2x agonist, alpha 1 beta-methylene-ATP also significantly increased [Ca2+]i in HF cells, whereas the P2y agonist methylthio-ATP showed only a small [Ca2+]i response. Diadenosine polyphosphates mainly induced transplasmamembrane Ca2+ influx as was confirmed by experiments in the absence of extracellular Ca2+ or by manganese quenching studies. Organic (verapamil) and inorganic Ca2+ channel blockers (NiCI2) significantly reduced the AP6A induced transplasmamembrane Ca2+ influx. The inhibitor of phosphatidylcholine-specific phospholipase C, D609, significantly reduced the effect of diadenosine polyphosphates on [Ca2+]i in HF cells. It is concluded that diadenosine polyphosphates regulate transplasmamembrane Ca2+ influx after occupation of P2x receptors via activation of phosphatidylcholine-specific phospholipase C and hence of voltage-operated Ca2+ channels.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bridged-Ring Compounds / pharmacology
  • Calcium / metabolism*
  • Calcium Channel Blockers / pharmacology
  • Cells, Cultured
  • Cytosol / metabolism
  • Dinucleoside Phosphates / pharmacology*
  • Fibroblasts
  • Fura-2 / metabolism
  • Humans
  • Manganese / pharmacology
  • Nickel / pharmacology
  • Norbornanes
  • Phosphodiesterase Inhibitors / pharmacology
  • Purinergic Antagonists
  • Receptors, Purinergic / metabolism*
  • Suramin / pharmacology
  • Theobromine / analogs & derivatives
  • Theobromine / pharmacology
  • Thiocarbamates
  • Thiones / pharmacology
  • Type C Phospholipases / antagonists & inhibitors
  • Type C Phospholipases / metabolism*
  • Vasoconstrictor Agents / pharmacology
  • Verapamil / pharmacology
  • Xanthines / pharmacology

Substances

  • Bridged-Ring Compounds
  • Calcium Channel Blockers
  • Dinucleoside Phosphates
  • Norbornanes
  • Phosphodiesterase Inhibitors
  • Purinergic Antagonists
  • Receptors, Purinergic
  • Thiocarbamates
  • Thiones
  • Vasoconstrictor Agents
  • Xanthines
  • Manganese
  • P(1),P(5)-di(adenosine-5'-)pentaphosphate
  • diadenosine 5',5''''-P1,P6-hexaphosphate
  • tricyclodecane-9-yl-xanthogenate
  • 3,7-dimethyl-1-propargylxanthine
  • Suramin
  • nickel chloride
  • Nickel
  • 1,3-dipropyl-8-cyclopentylxanthine
  • Verapamil
  • Type C Phospholipases
  • Theobromine
  • Calcium
  • Fura-2